John Newell‐Price
YOU?
Author Swipe
View article: Efficacy and Tolerability of Metyrapone in Mild Autonomous Cortisol Secretion: Real‐World Findings From Clinical Practice
Efficacy and Tolerability of Metyrapone in Mild Autonomous Cortisol Secretion: Real‐World Findings From Clinical Practice Open
Objective Mild autonomous cortisol secretion (MACS) is associated with increased cardiometabolic risk factors including hypertension, type 2 diabetes and dyslipidaemia. By using evening doses of metyrapone, a short‐acting 11‐β hydroxylase …
View article: Benign Adrenal Adenomas Are Associated With Reduced Prevalence of Hospitalised Patients With COVID‐19
Benign Adrenal Adenomas Are Associated With Reduced Prevalence of Hospitalised Patients With COVID‐19 Open
Introduction Adrenal incidentalomas (AI) are commonly found on imaging done for indications other than to assess the adrenal glands. Prevalence increases with age and is around 10% in people over 80 years. The majority of AIs are benign ad…
View article: Diagnostic performance of morning serum cortisol for glucocorticoid weaning in children and adults
Diagnostic performance of morning serum cortisol for glucocorticoid weaning in children and adults Open
Design Morning cortisol predicts the outcome of the short synacthen test (SST). There is a paucity of studies examining this in a dedicated cohort of children and adults weaning off glucocorticoids and using a modern immunoassay. This stud…
View article: Osilodrostat dose impact on efficacy/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4
Osilodrostat dose impact on efficacy/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4 Open
Objectives Evaluate how osilodrostat dose and baseline mean urinary free cortisol (mUFC) affect treatment outcomes and provide evidence-based guidance on personalized medical treatment for patients with Cushing's disease. Methods/design In…
View article: MON-491 Long term outcomes in patients assessed by Waking Salivary Cortisone as a screening test for adrenal insufficiency
MON-491 Long term outcomes in patients assessed by Waking Salivary Cortisone as a screening test for adrenal insufficiency Open
Disclosure: E. Loh: None. C. Elder: None. J.D. Newell-Price: Diurnal, Crinetics, Recordati, HRA Pharmaceuticals. R.J. Ross: Diurnal. M. Debono: None. Background: Adrenal insufficiency (AI) is a prevalent condition globally. While the adren…
View article: OR07-08 A Double-blind Study of Modified-release Hydrocortisones, Chronocort versus Plenadren, in Adrenal Insufficiency (CHAMPAIN)
OR07-08 A Double-blind Study of Modified-release Hydrocortisones, Chronocort versus Plenadren, in Adrenal Insufficiency (CHAMPAIN) Open
Disclosure: A. Prete: None. V. Theiler-Schwetz: None. W. Arlt: None. I.O. Chifu: None. B. Harbeck: None. C. Napier: None. J.D. Newell-Price: None. A. Rees: None. N. Reisch: None. G.K. Stalla: None. H. Coope: Neurocrine Biosciences. K. Malt…
View article: Long-term outcomes in patients with congenital adrenal hyperplasia treated with hydrocortisone modified-release hard capsules
Long-term outcomes in patients with congenital adrenal hyperplasia treated with hydrocortisone modified-release hard capsules Open
Background Hydrocortisone modified-release hard capsules (MRHC, development name Chronocort) replace the physiological overnight cortisol rise and improve the biochemical control of congenital adrenal hyperplasia (CAH). Aim This study aims…
View article: Correction to: Osilodrostat improves blood pressure and glycemic control in patients with Cushing’s disease: a pooled analysis of LINC 3 and LINC 4 studies
Correction to: Osilodrostat improves blood pressure and glycemic control in patients with Cushing’s disease: a pooled analysis of LINC 3 and LINC 4 studies Open
View article: Modelling adrenal steroid profiles to inform monitoring guidance in congenital adrenal hyperplasia
Modelling adrenal steroid profiles to inform monitoring guidance in congenital adrenal hyperplasia Open
Diurnal; MRC; NIH; NIHR.
View article: Switching Patients With Congenital Adrenal Hyperplasia to Modified‐Release Hydrocortisone Capsules: Relative Bioavailability and Disease Control
Switching Patients With Congenital Adrenal Hyperplasia to Modified‐Release Hydrocortisone Capsules: Relative Bioavailability and Disease Control Open
Background Replacement therapy with modified‐release hydrocortisone capsules (MRHC) restores the physiological circadian cortisol rhythm in congenital adrenal hyperplasia (CAH). Aims To determine the relative bioavailability of MRHC and ev…
View article: Conservatively managed non-functioning pituitary macroadenomas—cohort study from the UK Non-functioning Pituitary Adenoma Consortium
Conservatively managed non-functioning pituitary macroadenomas—cohort study from the UK Non-functioning Pituitary Adenoma Consortium Open
Objective Surveillance is often adopted for asymptomatic non-functioning pituitary macroadenomas (macroNFPAs). Due to low-quality evidence, uncertainty remains on optimal frequency of imaging/biochemical monitoring and indications for surg…
View article: Blood pressure and its associations in 554 children and young people with congenital adrenal hyperplasia
Blood pressure and its associations in 554 children and young people with congenital adrenal hyperplasia Open
Background Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) affects approximately 1 in 15 000 individuals. We leveraged the power of multicentre registry data to assess the trend and predictors of blood pressur…
View article: Etomidate in Severe Cushing Syndrome: A Systematic Review
Etomidate in Severe Cushing Syndrome: A Systematic Review Open
Background Severe Cushing syndrome is a medical emergency. Etomidate is the only IV option available for treating hypercortisolism, especially in critically ill patients obviating oral medications. Methods A systematic review and meta-anal…
View article: Osilodrostat improves blood pressure and glycemic control in patients with Cushing’s disease: a pooled analysis of LINC 3 and LINC 4 studies
Osilodrostat improves blood pressure and glycemic control in patients with Cushing’s disease: a pooled analysis of LINC 3 and LINC 4 studies Open
Purpose To evaluate the effect of osilodrostat and hypercortisolism control on blood pressure (BP) and glycemic control in patients with Cushing’s disease. Methods Pooled analysis of two Phase III osilodrostat studies (LINC 3 and LINC 4), …
View article: Improved Clinical Outcomes During Long-term Osilodrostat Treatment of Cushing Disease With Normalization of Late-night Salivary Cortisol and Urinary Free Cortisol
Improved Clinical Outcomes During Long-term Osilodrostat Treatment of Cushing Disease With Normalization of Late-night Salivary Cortisol and Urinary Free Cortisol Open
Purpose To assess whether simultaneous normalization of late-night salivary cortisol (LNSC) and mean urinary free cortisol (mUFC) in patients with Cushing disease treated with osilodrostat is associated with better clinical outcomes than c…
View article: 7898 A Case of Dual Secreting Adrenal Lesion With Multiple Complications Resulting From Hormonal Abnormalities
7898 A Case of Dual Secreting Adrenal Lesion With Multiple Complications Resulting From Hormonal Abnormalities Open
Disclosure: B. Riaz: None. V. Muraleedharan: None. D. Fernando: None. S. Balasubramanian: None. J. Newell-Price: None. Introduction: Dual secreting adrenal tumours with catecholamine and ACTH secretion are rare. This dual secretion may alt…
View article: 6437 Analysis of 17-OH-Progesterone (17OHP) and Androstenedione (A4) Profiles To Rationalise Biochemical Monitoring Of CAH Patients
6437 Analysis of 17-OH-Progesterone (17OHP) and Androstenedione (A4) Profiles To Rationalise Biochemical Monitoring Of CAH Patients Open
Disclosure: N.R. Lawrence: None. N.P. Krone: None. J.F. Dawson: None. Z. Lang: None. W. Arlt: Advisory Board Member; Self; Diurnal. A. Brac de la Perriere: Research Investigator; Self; Diurnal. A.L. Hirschberg: Research Investigator; Self;…
View article: 6907 Continued Improvements in Hypertension and Diabetes During Long-Term Osilodrostat Therapy in Patients with Cushing’s Disease: A Pooled Analysis from the Phase III LINC 3 and LINC 4 Studies
6907 Continued Improvements in Hypertension and Diabetes During Long-Term Osilodrostat Therapy in Patients with Cushing’s Disease: A Pooled Analysis from the Phase III LINC 3 and LINC 4 Studies Open
Disclosure: M. Fleseriu: Advisory Board Member; Self; Recordati Rare Diseases. Consulting Fee; Self; Recordati Rare Diseases, Sparrow, Xeris Pharmaceuticals (Strongbridge). Grant Recipient; Self; Recordati Rare Diseases, Sparrow, Xeris Pha…
View article: 6927 Metyrapone To Reset The Nocturnal Cortisol Rhythm In Mild Autonomous Cortisol Secretion (MACS) - Safety And Impact On Cardiometabolic Risk Factors
6927 Metyrapone To Reset The Nocturnal Cortisol Rhythm In Mild Autonomous Cortisol Secretion (MACS) - Safety And Impact On Cardiometabolic Risk Factors Open
Disclosure: S. Berry: None. A. Iqbal: None. J.D. Newell-Price: Consulting Fee; Self; HRA Pharmaceuticals. M. Debono: Consulting Fee; Self; HRA Pharmaceuticals. Grant Recipient; Self; HRA Pharmaceuticals. Speaker; Self; HRA Pharmaceuticals.…
View article: 6589 Antisense Oligonucleotides for Reducing ACTH Secretion in a Model of Cushing's Disease
6589 Antisense Oligonucleotides for Reducing ACTH Secretion in a Model of Cushing's Disease Open
Disclosure: M.S. Varughese: None. H. Eltumi: None. E.H. Kemp: None. J.D. Newell-Price: None. Antisense Oligonucleotides for Reducing ACTH Secretion in a Model of Cushing’s Disease Background: Cushing’s disease (CD) is a multi-system disord…
View article: 9341 CHAMPAIN Study: Initial Results From A Phase II Study Of Efficacy, Safety And Tolerability Of Modified-release Hydrocortisones: Chronocort® (Efmody®) Versus Plenadren®, In Primary Adrenal Insufficiency
9341 CHAMPAIN Study: Initial Results From A Phase II Study Of Efficacy, Safety And Tolerability Of Modified-release Hydrocortisones: Chronocort® (Efmody®) Versus Plenadren®, In Primary Adrenal Insufficiency Open
Disclosure: A. Prete: Research Investigator; Self; Diurnal. V. Theiler-Schwetz: Research Investigator; Self; Diurnal. W. Arlt: Research Investigator; Self; Diurnal. I.O. Chifu: Research Investigator; Self; Diurnal. B. Harbeck: Research Inv…
View article: 7692 Morning Cortisol Levels In Patients With Established Primary Adrenal Insufficiency
7692 Morning Cortisol Levels In Patients With Established Primary Adrenal Insufficiency Open
Disclosure: A. Prete: Research Investigator; Self; Diurnal. V. Theiler-Schwetz: Research Investigator; Self; Diurnal. W. Arlt: Research Investigator; Self; Diurnal. I.O. Chifu: Research Investigator; Self; Diurnal. B. Harbeck: Research Inv…
View article: 12670 CHAMPAIN Study: Initial Results From A Phase II Study Of Efficacy, Safety And Tolerability Of Modified-release Hydrocortisones: Chronocort® (Efmody®) Versus Plenadren®, In Primary Adrenal Insufficiency
12670 CHAMPAIN Study: Initial Results From A Phase II Study Of Efficacy, Safety And Tolerability Of Modified-release Hydrocortisones: Chronocort® (Efmody®) Versus Plenadren®, In Primary Adrenal Insufficiency Open
Disclosure: A. Prete: Research Investigator; Self; Diurnal. V. Theiler-Schwetz: Research Investigator; Self; Diurnal. W. Arlt: Research Investigator; Self; Diurnal. I.O. Chifu: Research Investigator; Self; Diurnal. B. Harbeck: Research Inv…
View article: 7061 Incidence of Adrenal Crisis In Congenital Adrenal Hyperplasia (CAH) Patients During A Prospective Monitored Long-Term Study Of Modified-Release Hydrocortisone (MRHC) Capsules, (Efmody)
7061 Incidence of Adrenal Crisis In Congenital Adrenal Hyperplasia (CAH) Patients During A Prospective Monitored Long-Term Study Of Modified-Release Hydrocortisone (MRHC) Capsules, (Efmody) Open
Disclosure: R.J. Ross: Consulting Fee; Self; Diurnal. D.P. Merke: Research Investigator; Self; Diurnal. A. Mallappa: Research Investigator; Self; Diurnal. W. Arlt: Research Investigator; Self; Diurnal. A. Brac de la Perriere: Research Inve…
View article: Approach to the Patient With Suspected Hypotonic Polyuria
Approach to the Patient With Suspected Hypotonic Polyuria Open
Investigation and management of hypotonic polyuria is a common challenge in clinical endocrinology. The 3 main causes, recently renamed to arginine vasopressin deficiency (AVP-D, formerly central diabetes insipidus), arginine vasopressin r…
View article: Comparison of modified-release hydrocortisone capsules versus prednisolone in the treatment of congenital adrenal hyperplasia
Comparison of modified-release hydrocortisone capsules versus prednisolone in the treatment of congenital adrenal hyperplasia Open
Background Prednisolone and prednisone are recommended treatment options for adults with congenital adrenal hyperplasia (CAH); however, there is no randomised comparison of prednis(ol)one with hydrocortisone. Design Six-month open-label ra…
View article: Maximizing the Sensitivity of Bilateral Inferior Petrosal Sinus Sampling
Maximizing the Sensitivity of Bilateral Inferior Petrosal Sinus Sampling Open
View article: Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease
Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease Open
View article: A Retrospective Study on Weaning Glucocorticoids and Recovery of the Hypothalamic–Pituitary–Adrenal Axis
A Retrospective Study on Weaning Glucocorticoids and Recovery of the Hypothalamic–Pituitary–Adrenal Axis Open
Context Glucocorticoids suppress the hypothalamic–pituitary–adrenal (HPA) axis, resulting in tertiary adrenal insufficiency (AI). When weaning patients off glucocorticoids there is no consensus on whether to maintain patients on prednisolo…
View article: High prevalence of venous thrombotic events in Cushing's syndrome: data from ERCUSYN and details in relation to surgery
High prevalence of venous thrombotic events in Cushing's syndrome: data from ERCUSYN and details in relation to surgery Open
Objective The aim of this study was to evaluate the prevalence of venous thromboembolism (VTE) in patients included in the European Registry on Cushing's syndrome (ERCUSYN), compare their clinical characteristics with those who did not dev…